Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents

References

• ShawJESicreeRAZimmetPZGlobal estimates of the prevalence of diabetes for 2010 and 2030Diabetes Res Clin Pract201087141419896746
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation (IDF)IDF Diabetes Atlas6th edBrusselsInternational Diabetes Federation2013
   Google Scholar
• CasagrandeSSFradkinJESaydahSHRustKFCowieCCThe prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010Diabetes Care20133682271227923418368
   PubMed Web of Science ®Google Scholar
• BeckerMLPearsonERTkáčIPharmacogenetics of oral antidiabetic drugsInt J Endocrinol2013201368631524324494
   PubMed Web of Science ®Google Scholar
• DeFronzoRAStonehouseAHHanJWintleMERelationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trialsDiabetic Med201027330931720536494
   PubMed Web of Science ®Google Scholar
• HoPMRumsfeldJSMasoudiFAEffect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitusArch Intern Med2006166171836184117000939
   PubMed Web of Science ®Google Scholar
• ZhouKDonnellyLYangJHeritability of variation in glycaemic response to metformin: a genome-wide complex trait analysisLancet Diabetes Endocrinol20142648148724731673
   PubMed Web of Science ®Google Scholar
• ZhouKBellenguezCSpencerCCCommon variants near ATM are associated with glycemic response to metformin in type 2 diabetesNat Genet201143211712021186350
   PubMed Web of Science ®Google Scholar
• VellaAPharmacogenetics for type 2 diabetes: practical considerations for study designJ Diabetes Sci Technol20093470570920144317
   PubMedGoogle Scholar
• WatanabeITomitaAShimizuMA study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitusClin Pharmacol Ther200373543545512732844
   PubMed Web of Science ®Google Scholar
• KumashiroRKubotaTKogaYAssociation of troglitazone-induced liver injury with mutation of the cytochrome P450 2C19 geneHepatol Res200326433734212963435
   PubMed Web of Science ®Google Scholar
• DonnellyLADoneyASHattersleyATMorrisADPearsonERThe effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetesDiabet Med200623212813316433709
   PubMed Web of Science ®Google Scholar
• OngCRMolyneauxLMConstantinoMITwiggSMYueDKLong-term efficacy of metformin therapy in nonobese individuals with type 2 diabetesDiabetes Care200629112361236417065668
   PubMed Web of Science ®Google Scholar
• MiyazakiYDe FilippisEBajajMWajcbergEGlassLCTriplittCPredictors of improved glycemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physicianBr J Diabetes Vasc Dis200552835
   Google Scholar
• KimYMChaBSKimDJPredictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitusDiabetes Res Clin Pract200567435215620433
   PubMed Web of Science ®Google Scholar
• ScheenAJDrug interactions of clinical importance with antihyperglycaemic agents: an updateDrug Saf200528760163115963007
   PubMed Web of Science ®Google Scholar
• DujicTZhouKDonnellyLATavendaleRPalmerCNPearsonERAssociation of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS StudyDiabetes20156451786179325510240
   PubMed Web of Science ®Google Scholar
• NiemiMBackmanJTNeuvonenMNeuvonenPJEffects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinideDiabetologia20034634735112687332
   PubMed Web of Science ®Google Scholar
• GoswamiSYeeSWStockerSGenetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metforminClin Pharmacol Ther201496337037924853734
   PubMed Web of Science ®Google Scholar
• DeFronzoRAPharmacologic therapy for type 2 diabetes mellitusAnn Intern Med1999131428130310454950
   PubMed Web of Science ®Google Scholar
• HanTHEverettRSProctorWROrganic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytesMol Pharmacol201384218218923680637
   PubMed Web of Science ®Google Scholar
• HanTKProctorWRCostalesCLCaiHEverettRSThakkerDRFour cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayersJ Pharmacol Exp Ther2015352351952825563903
   PubMed Web of Science ®Google Scholar
• MüllerJLipsKSMetznerLNeubertRHKoepsellHBrandschMDrug specificity and intestinal membrane localization of human organic cation transporters (OCT)Biochem Pharmacol200570121851186016263091
   PubMed Web of Science ®Google Scholar
• GrahamGGPuntJAroraMClinical pharmacokinetics of metforminClin Pharmacokinet2011502819821241070
   PubMed Web of Science ®Google Scholar
• KimuraNMasudaSTaniharaYMetformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1Drug Metab Pharmacokinet200520537938616272756
   PubMedGoogle Scholar
• OtsukaMMatsumotoTMorimotoRAriokaSOmoteHMoriyamaYA human transporter protein that mediates the final excretion step for toxic organic cationsProc Natl Acad Sci USA200510250179231792816330770
   PubMed Web of Science ®Google Scholar
• PernicovaIKorbonitsMMetformin – mode of action and clinical implications for diabetes and cancerNat Rev Endocrinol201410314315624393785
   PubMed Web of Science ®Google Scholar
• ForetzMHébrardSLeclercJMetformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy stateJ Clin Invest201012072355236920577053
   PubMed Web of Science ®Google Scholar
• MillerRAChuQXieJForetzMViolletBBirnbaumMJBiguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMPNature2013494743625626023292513
   PubMed Web of Science ®Google Scholar
• MadirajuAKErionDMRahimiYMetformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenaseNature2014510750654254624847880
   PubMed Web of Science ®Google Scholar
• MaruthurNMGribbleMOBennettWLThe pharmacogenetics of type 2 diabetes: a systematic reviewDiabetes Care20143787688624558078
   PubMed Web of Science ®Google Scholar
• NiesATKoepsellHDammeKSchwabMOrganic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapyHandb Exp Pharmacol201120110516721103969
   PubMedGoogle Scholar
• TzvetkovMVVormfeldeSVBalenDThe effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metforminClin Pharmacol Ther200986329930619536068
   PubMed Web of Science ®Google Scholar
• ChristensenMMBrasch-AndersenCGreenHThe pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1cPharmacogenet Genomics2011211283785021989078
   PubMed Web of Science ®Google Scholar
  Erratum in Pharmacogenet Genomics20152514850
   Web of Science ®Google Scholar
• ShuYBrownCCastroRAEffect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokineticsClin Pharmacol Ther200883227328017609683
   PubMed Web of Science ®Google Scholar
• ZhouKDonnellyLAKimberCHReduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTs studyDiabetes20095861434143919336679
   PubMed Web of Science ®Google Scholar
• DavisRGiacominiKYeeSWJenkinsGMcCartyCAWilkeRAPS1-10: response to metformin and genetic variants of organic cation and multidrug and toxin extrusion transportersClin Med Res201083–4191
   Google Scholar
• BeckerMLVisserLEvan SchaikRHHofmanAUitterlindenAGStrickerBHGenetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitusPharmacogenomics J20099424224719381165
   PubMed Web of Science ®Google Scholar
• JablonskiKAMcAteerJBde BakkerPIDiabetes Prevention Program Research GroupCommon variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention programDiabetes201059102672268120682687
   PubMed Web of Science ®Google Scholar
• TarasovaLKalninaIGeldnereKAssociation of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patientsPharmacogenet Genomics201222965966622735389
   PubMed Web of Science ®Google Scholar
• SongISShinHJShimEJGenetic variants of the organic cation transporter 2 influence the disposition of metforminClin Pharmacol Ther200884555956218401339
   PubMed Web of Science ®Google Scholar
• ShikataEYamamotoRTakaneHHuman organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metforminJ Hum Genet200752211712217111267
   PubMed Web of Science ®Google Scholar
• HouWZhangDLuWPolymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patientsMol Diagn Ther2015191253325573751
   PubMed Web of Science ®Google Scholar
• ChenYLiSBrownCEffect of genetic variation in the organic cation transporter 2 on the renal elimination of metforminPharmacogenet Genomics200919749750419483665
   PubMed Web of Science ®Google Scholar
• ChristensenMMPedersenRSStageTBA gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metforminPharmacogenet Genomics2013231052653423873119
   PubMed Web of Science ®Google Scholar
• KajiwaraMTeradaTOgasawaraKIdentification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activityJ Hum Genet2009541404619158817
   PubMed Web of Science ®Google Scholar
• ChoiJHYeeSWRamirezAHA common 5′-UTR variant in MATE2-K is associated with poor response to metforminClin Pharmacol Ther201190567468421956618
   PubMed Web of Science ®Google Scholar
• HeRZhangDLuWSLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patientsDiabetes Res Clin Pract20151091576326004431
   PubMed Web of Science ®Google Scholar
• TkáčIKlimčákováLJavorskýMPharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetesDiabetes Obes Metab201315218919122882994
   PubMed Web of Science ®Google Scholar
• BeckerMLVisserLEvan SchaikRHHofmanAUitterlindenAGStrickerBHGenetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary studyDiabetes200958374574919228809
   PubMed Web of Science ®Google Scholar
• StockerSLMorrisseyKMYeeSWThe effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metforminClin Pharmacol Ther201393218619423267855
   PubMed Web of Science ®Google Scholar
• BeckerMLVisserLEvan SchaikRHHofmanAUitterlindenAGStrickerBHInteraction between polymorphisms in the OCT1 and MATE1 transporter and metformin responsePharmacogenet Genomics2010201384419898263
   PubMed Web of Science ®Google Scholar
• van LeeuwenNNijpelsGBeckerMLA gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohortsDiabetologia20125571971197722453232
   PubMed Web of Science ®Google Scholar
• ZhouYGuoYYeWrs11212617 is associated with metformin treatment response in type 2 diabetes in Shanghai local Chinese populationInt J Clin Pract201468121462146625296556
   PubMed Web of Science ®Google Scholar
• FlorezJCJablonskiKATaylorADiabetes Prevention Program Research GroupThe C allele of ATM rs11212617 does not associate with metformin response in the diabetes prevention programDiabetes Care20123591864186722751958
   PubMed Web of Science ®Google Scholar
• DesaiNRShrankWHFischerMAPatterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implicationsAm J Med20121253302.e1302.e722340932
   PubMed Web of Science ®Google Scholar
• KirchheinerJRootsIGoldammerMEffect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevanceClin Pharmacokinet200544121209122516372821
   PubMed Web of Science ®Google Scholar
• XuHMurrayMMcLachlanAJInfluence of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of sulfonylurea drugsCurr Drug Metab20091064365819799532
   PubMed Web of Science ®Google Scholar
• ShyngSNicholsCGOctameric stoichiometry of the KATP channel complexJ Gen Physiol199711066556649382894
   PubMed Web of Science ®Google Scholar
• GoldsteinJAClinical relevance of genetic polymorphisms in the human CYP2C subfamilyBr J Clin Pharmacol200152434935511678778
   PubMed Web of Science ®Google Scholar
• KirchheinerJBrockmöllerJMeinekeIImpact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteersClin Pharmacol Ther200271428629611956512
   PubMed Web of Science ®Google Scholar
• YinOQTomlinsonBChowMSCYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjectsClin Pharmacol Ther200578437037716198656
   PubMed Web of Science ®Google Scholar
• ShonJHYoonYRKimKAEffects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humansPharmacogenetics200212211111911875365
   PubMedGoogle Scholar
• WangRChenKWenSYLiJWangSQPharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphismsClin Pharmacol Ther2005781909216003298
   PubMed Web of Science ®Google Scholar
• ZhangYSiDChenXInfluence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjectsBr J Clin Pharmacol2007641677417298483
   PubMed Web of Science ®Google Scholar
• ZhouKDonnellyLBurchLLoss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS studyClin Pharmacol Ther2010871525619794412
   PubMed Web of Science ®Google Scholar
• BeckerMLVisserLETrienekensPHHofmanAvan SchaikRHStrickerBHCytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitusClin Pharmacol Ther200883228829217597710
   PubMed Web of Science ®Google Scholar
• SuzukiKYanagawaTShibasakiTKaniwaNHasegawaRTohkinMEffect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetesDiabetes Res Clin Pract200672214815416325295
   PubMed Web of Science ®Google Scholar
• HattersleyATAshcroftFMActivating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapyDiabetes20055492503251316123337
   PubMed Web of Science ®Google Scholar
• PearsonERFlechtnerINjølstadPRNeonatal Diabetes International Collaborative GroupSwitching from insulin to oral sulfonylureas in patients with diabetes due to Kir62 mutationsN Engl J Med2006355546747716885550
   PubMed Web of Science ®Google Scholar
• LangVYFatehiMLightPEPharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369APharmacogenet Genomics201222320621422209866
   PubMed Web of Science ®Google Scholar
• ZhangHLiuXKuangHYiRXingHAssociation of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetesDiabetes Res Clin Pract2007771586117118480
   PubMed Web of Science ®Google Scholar
• FengYMaoGRenXSer1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patientsDiabetes Care200831101939194418599530
   PubMed Web of Science ®Google Scholar
• LiQChenMZhangRKCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patientsClin Exp Pharmacol Physiol2014411074875425115353
   PubMed Web of Science ®Google Scholar
• JavorskyMKlimcakovaLSchronerZKCNJ11 gene E23K variant and therapeutic response to sulfonylureasEur J Intern Med201223324524922385882
   PubMed Web of Science ®Google Scholar
• GloynALHashimYAshcroftSJUK Prospective Diabetes Study (UKPDS 53)Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir62 with Type 2 diabetes mellitus (UKPDS 53)Diabet Med200118320621211318841
   PubMed Web of Science ®Google Scholar
• SestiGLarattaECardelliniMThe E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir62 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetesJ Clin Endocrinol Metab20069162334233916595597
   PubMed Web of Science ®Google Scholar
• RagiaGTavridouAPetridisIManolopoulosVGAssociation of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patientsDiabetes Res Clin Pract201298111912422591706
   PubMed Web of Science ®Google Scholar
• ShuLSauterNSSchulthessFTMatveyenkoAVOberholzerJMaedlerKTranscription factor 7-like 2 regulates beta-cell survival and function in human pancreatic isletsDiabetes200857364565318071026
   PubMed Web of Science ®Google Scholar
• GrantSFThorleifssonGReynisdottirIVariant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetesNat Genet200638332032316415884
   PubMed Web of Science ®Google Scholar
• PearsonERDonnellyLAKimberCVariation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs studyDiabetes20075682178218217519421
   PubMed Web of Science ®Google Scholar
• SchronerZJavorskyMTkacovaREffect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetesDiabetes Obes Metab2011131899121114608
   PubMed Web of Science ®Google Scholar
• JavorskýMBabjakováEKlimčákováLAssociation between TCF7L2 genotype and glycemic control in diabetic patients treated with gliclazideInt J Endocrinol2013201337485823509454
   PubMed Web of Science ®Google Scholar
• HolsteinAHahnMKörnerAStumvollMKovacsPTCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetesBMC Med Genet2011123021349175
   PubMed Web of Science ®Google Scholar
• BachmakovIGlaeserHFrommMFKönigJInteraction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1Diabetes20085761463146918314419
   PubMed Web of Science ®Google Scholar
• NiemiMBackmanJTKajosaariLIPolymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokineticsClin Pharmacol Ther200577646847815961978
   PubMed Web of Science ®Google Scholar
• KalliokoskiANeuvonenMNeuvonenPJNiemiMDifferent effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinideJ Clin Pharmacol200848331132118187595
   PubMed Web of Science ®Google Scholar
• ZhangWHeYJHanCTEffect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinideBr J Clin Pharmacol200662556757216796707
   PubMed Web of Science ®Google Scholar
• ChengYWangGZhangWFanLChenYZhouHHEffect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteersEur J Clin Pharmacol201369340741322842957
   PubMed Web of Science ®Google Scholar
• KalliokoskiABackmanJTNeuvonenPJNiemiMEffects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinidePharmacogenet Genomics2008181193794218854776
   PubMed Web of Science ®Google Scholar
• KirchheinerJMeinekeIMüllerGInfluence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteersClin Pharmacokinet200443426727815005635
   PubMed Web of Science ®Google Scholar
• NiemiMLeathartJBNeuvonenMBackmanJTDalyAKNeuvonenPJPolymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinideClin Pharmacol Ther200374438038714534525
   PubMed Web of Science ®Google Scholar
• HeYYZhangRShaoXYAssociation of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patientsActa Pharmacol Sin200829898398918664331
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care20153814014925538310
   PubMed Web of Science ®Google Scholar
• LevinDBellSSundRScottish Diabetes Research Network Epidemiology Group; Diabetes and Cancer Research ConsortiumPioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysisDiabetologia201558349350425481707
   PubMed Web of Science ®Google Scholar
• LewisJMFerraraAPengTRisk of bladder cancer among diabetic patients treated with pioglitazone interim report of a longitudinal cohort studyDiabetes Care20083491692221447663
   PubMed Web of Science ®Google Scholar
• KalliokoskiANeuvonenPJNiemiMSLCO1B1 polymorphism and oral antidiabetic drugsBasic Clin Pharmacol Toxicol2010107477578120406215
   PubMed Web of Science ®Google Scholar
• KirchheinerJThomasSBauerSPharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotypeClin Pharmacol Ther200680665766717178266
   PubMed Web of Science ®Google Scholar
• AquilanteCLBushmanLRKnutsenSDBurtLERomeLCKosmiskiLAInfluence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteersHum Genomics20083171619129086
   PubMedGoogle Scholar
• AquilanteCLKosmiskiLABourneDWImpact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazoneBr J Clin Pharmacol201375121722622625877
   PubMed Web of Science ®Google Scholar
• TornioANiemiMNeuvonenPJBackmanJTTrimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazoneDrug Metab Dispos2008361738017913794
   PubMed Web of Science ®Google Scholar
• KalliokoskiANeuvonenMNeuvonenPJNiemiMNo significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazoneBr J Clin Pharmacol2008651788617635496
   PubMed Web of Science ®Google Scholar
• AltshulerDHirschhornJNKlannemarkMThe common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetesNat Genet2000261768010973253
   PubMed Web of Science ®Google Scholar
• HsiehMCLinKDTienKJCommon polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitusMetabolism20105981139114420045142
   PubMed Web of Science ®Google Scholar
• PeiQHuangQYangGPPPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients’ response to pioglitazone in ChinaActa Pharmacol Sin201334225526123147557
   PubMed Web of Science ®Google Scholar
• KangESParkSYKimHJEffects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetesClin Pharmacol Ther200578220220816084854
   PubMed Web of Science ®Google Scholar
• BaileySDXieCDoRVariation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) studyDiabetes Care201033102250225320628086
   PubMed Web of Science ®Google Scholar
• DruckerDJNauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet200636895481696170517098089
   PubMed Web of Science ®Google Scholar
• HolstJJThe physiology of glucagon-like peptide 1Physiol Rev20078741409143917928588
   PubMed Web of Science ®Google Scholar
• SathananthanAManCDMichelettoFCommon genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot studyDiabetes Care20103392074207620805279
   PubMed Web of Science ®Google Scholar
• ’t HartLMFritscheANijpelsGThe CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathwayDiabetes20136293275328123674605
   PubMed Web of Science ®Google Scholar
• ScheenAJPharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney diseaseClin Pharmacokinet201554769170825805666
   PubMed Web of Science ®Google Scholar
• FranckeSMamidiRNSolankiBIn vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humansJ Clin Pharmacol20155591061107225827774
   PubMed Web of Science ®Google Scholar
• ScheenAJPharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitusDrugs2015751335925488697
   PubMed Web of Science ®Google Scholar
• van den HeuvelLPAssinkKWillemsenMMonnensLAutosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)Hum Genet2002111654454712436245
   PubMed Web of Science ®Google Scholar
• CaladoJSotoKClementeCCorreiaPRueffJNovel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuriaHum Genet2004114331431614614622
   PubMed Web of Science ®Google Scholar
• RafiqMFlanaganSEPatchAMNeonatal Diabetes International Collaborative GroupEffective treatment with diabetes due to sulfonylurea receptor 1 (SUR1) mutationsDiabetes Care200832220420918025408
   PubMed Web of Science ®Google Scholar